IL6 and diffuse large B-cell lymphoma: Studies have shown that IL-6, a cytokine induced by NF-κB, promotes DLBCL migration by activating the migration mechanism driven by JAK-STAT, promotes the progression and drug resistance of DLBCL and is related to the poor prognosis of DLBCL patients [30–32].